ストックスクリーナーアプリを入手
7.38
6.11%
-0.48
プレマーケット:
7.38
Tonix Pharmaceuticals Holding Corp (TNXP) 最新ニュース
Global Artificial Intelligence in Drug Commercialization Market to Observe Stupendous Growth at a CAGR of ~24% by 2032 | DelveInsight - GlobeNewswire Inc.
Tonix Pharm stock plunges to 52-week low of $7.84 By Investing.com - Investing.com Australia
Tonix Pharm stock plunges to 52-week low of $7.84 - Investing.com
Tonix reports positive results in TNX-1500 phase 1 trial - MSN
TNXP: PDUFA Date for TNX-102 SL in Fibromyalgia of August 15, 2025 - Smartkarma
TNXP: PDUFA Date for TNX-102 SL in Fibromyalgia of August 15, 2025… - Yahoo Finance
(TNXP) Investment Analysis - Stock Traders Daily
(TNXP) On The My Stocks Page - Stock Traders Daily
Tonix Pharmaceuticals appoints new CTO amid drug development - MSN
Tonix Pharmaceuticals reports positive phase 1 results for TNX-1500, advancing to Phase 2 - Proactive Investors USA
Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights - ADVFN
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap DownHere's Why - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap UpWhat's Next? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 13.2%Should You Buy? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 12.6%Time to Sell? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7%Should You Sell? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.7%What's Next? - MarketBeat
Tonix Pharma says it had about $98.8M in cash and cash equivalents as of Dec 31, 2024 - MSN
Tonix Pharmaceuticals Rises After Preliminary 2024 Results -February 07, 2025 at 03:39 pm EST - Marketscreener.com
Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash - GlobeNewswire
Tonix stock gains on business update, preliminary earnings report - Seeking Alpha
What's Going On With Tonix Pharmaceuticals Shares Friday? - Benzinga
Tonix Pharmaceuticals reports positive topline trial outcomes of TNX-1500 - Clinical Trials Arena
TNXP Financial Results: Strong Sales Growth & Strategic Cash Position Ahead of Critical FDA Date - StockTitan
Tonix Pharma Announces Promising Phase 1 Trial Results - TipRanks
Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases - GlobeNewswire
Breakthrough in Transplant Medicine: Novel Anti-CD40L Antibody Achieves Key Clinical Milestones - StockTitan
Tonix Pharmaceuticals announces reverse stock split - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated by Analysts at StockNews.com - MarketBeat
TNXPTonix Pharmaceuticals Holding Corp. Latest Stock News & Market Updates - StockTitan
Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference on February 10, 2025 - Nasdaq
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference - GlobeNewswire
Tonix's FDA Fast-Tracked Fibromyalgia Treatment Takes Center Stage at Major Investor Conference - StockTitan
Tonix Pharmaceuticals appoints new CTO amid drug development By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals promotes Fogarty to CTO - MSN
Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer - citybiz
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 7.7%Should You Sell? - MarketBeat
Tonix Pharma Promotes Fogarty to Chief Technology Officer - TipRanks
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Craters on Stock Split before FDA Call - TipRanks
Tonix's Leadership Shakeup: New CTO to Spearhead $34M Defense Contract & Critical FDA Review - StockTitan
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 11.5% HigherWhat's Next? - MarketBeat
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
3.13%
1.23%
大文字化:
|
ボリューム (24 時間):